NICM
SUPN icon

Neo Ivy Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Neo Ivy Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-292
Closed -$14.5K – 491
2025
Q4 		$14.5K Buy
292
+72
+33% +$3.5K ﹤0.01% 320
2025
Q3 		$10.5K Buy
+220
New +$8.86K ﹤0.01% 359

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's SUPN Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 292 shares — an estimated $14.5K sold.

Neo Ivy Capital Management first reported a position in SUPN in Q3 2025 and held it in 2 quarters. The position peaked at $14.5K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 292 Supernus Pharmaceuticals shares in Q1 2026, an estimated $14.5K.
  • Neo Ivy Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Neo Ivy Capital Management's Supernus Pharmaceuticals position peaked at $14.5K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.